Genmab shares rise on positive Rina-S ovarian cancer trial data
GMAB
Statements (5)
- Bullish
Genmab shares jumped
- Bullish
Genmab shares rose 8 percent on the Copenhagen Stock Exchange following a successful phase 3 trial result for a blood cancer treatment
- Bullish
Genmab shares jumped
- Bullish
Genmab stock rose 11% on positive cancer drug trial data
- Bullish
Jefferies raised its price target on Genmab following promising cancer data for its drug candidate Rina-S against ovarian cancer